Atara Biotherapeutics vs TScan Therapeutics
ATRA and TCRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ATRA and TCRX compare
Atara Biotherapeutics is the larger company, worth 7.1 times as much as TScan Therapeutics ($77.3M against $10.9M).
TScan Therapeutics grew revenue faster over the last twelve months (−38.4% versus −97.4% for Atara Biotherapeutics).
Atara Biotherapeutics keeps more of each dollar of sales as profit, with a net margin of −369% compared with −2219% at TScan Therapeutics.
Atara Biotherapeutics scores higher on the StockData Score (7 against 4 for TScan Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ATRA | TCRX |
|---|---|---|
| Size and price | ||
| Market cap | $77.3M | $10.9M |
| Share price | $7.70 | $0.161 |
| Change, 1 year | −38.3% | −86.5% |
| Change, 5 years | −98.3% | −98.2% |
| Beta (5Y) | 1.64 | 0.92 |
| Employees | 14 | 142 |
| StockData Score | ||
| Total score | 7 (better) | 4 |
| Valuation score | 0 | 3 (better) |
| Growth score | 1 (better) | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 19.5× | 2.1× (better) |
| P/B | – | 0.3× |
| FCF yield | – | −1026% |
| Fair value | – | $0.823 |
| Margin of safety | – | 80.5% |
| Growth | ||
| Revenue growth (TTM) | −97.4% | −38.4% (better) |
| Revenue growth, 5Y average | – | 56.9% |
| Net income growth (TTM) | −162% | – |
| Profitability | ||
| Operating margin | −344% (better) | −2247% |
| Net margin | −369% (better) | −2219% |
| FCF margin | – | −2153% |
| Return on equity | – | −126% |
| Financial health | ||
| Debt / equity | – | 0.87 |
| Interest coverage | – | −40.7× |
| Current ratio | 1.72 | 2.03 (better) |
| Altman Z-score | −154.05 | −8.20 (better) |
| Piotroski F-score | 5 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | −11.2% | – |
| Shareholder yield | −11.2% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 44.5% | 53.5% |
| Held by insiders | 55.5% | 32.8% |
| Insider net buying, 12 months | $2.0M (better) | $146K |
| Short interest, % of float | 6.6% | 4.4% |
Go deeper
- ATRA stock overview
- ATRA income statement
- ATRA valuation and score
- TCRX stock overview
- TCRX income statement
- TCRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.